Abstract

There have been many factors that predispose the patient with cancer or hematologic malignancy to infections. As neutropenia and fever have been frequently encountered in this immunecompromised patient group, mortality and morbidity rates are still high. The general approach to neutropenic patient all around the world follows a trend of standardization. Many therapeutic schemes have been created as the results of these standardization efforts. To us, the far most point that is reached at the moment is adapting the therapy to the patient, that is, individualization.